38978
document
MF101 , a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes : a phase II clinical trial . OBJECTIVE To determine the optimal dose , safety , and efficacy of an estrogen receptor beta selective Chinese herbal extract , menopausal formula 101 ( MF101 ) , for treating hot flushes . METHODS A randomized , blinded trial in 217 postmenopausal women with hot flushes randomized to 5 or 10 g/day of MF101 or placebo for 12 weeks . RESULTS The effects of 5 g/day of MF101 did not differ from those of placebo . After 12 weeks , the mean percent decrease in frequency of hot flushes in the 10 g/day group was 12.9 % greater than that in the placebo group ( P = 0.15 ) , the median percent decrease was 11.7 % greater than that in the placebo group ( P = 0.05 ) , and the proportion of women with at least a 50 % reduction in hot flushes was 16.2 % greater than that in the placebo group ( P = 0.03 ) . CONCLUSIONS Treatment with 10 g/day of MF101 reduces the frequency of hot flushes . Trials with higher doses are planned .
38979
Intervention_Pharmacological
MF101 , a selective estrogen receptor
38980
Intervention_Pharmacological
estrogen receptor beta selective Chinese herbal extract
38981
Intervention_Pharmacological
menopausal formula 101
38982
Intervention_Pharmacological
MF101
38983
Intervention_Control
placebo
38984
Intervention_Control
placebo
38985
Intervention_Control
placebo
38986
Intervention_Pharmacological
MF101
38987
Outcome_Other
mean percent decrease in frequency of hot flushes
38988
Outcome_Other
proportion of women with at least a 50 % reduction in hot flushes
38989
Participant_Sample-size
217
38990
Participant_Condition
postmenopausal
38991
Participant_Sex
women
38992
Participant_Condition
hot flushes